Acute Safety and Efficacy of Intranasal Esketamine Spray Plus an Oral Antidepressant in Patient With Treatment-Resistant Depression From a University Hospital in Korea
Aims: There is limited real-world evidence for patients with treatment-resistant depression (TRD) receiving esketamine nasal spray in Korea. This study is aimed to evaluate the acute safety and efficacy of intranasal esketamine in patients with TRD from a university hospital in Korea.
Saved in:
| Main Authors: | Sang-Yeol Lee, Kyung-Joon Min, Chan-Mo Yang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2025-06-01
|
| Series: | BJPsych Open |
| Online Access: | https://www.cambridge.org/core/product/identifier/S2056472425107989/type/journal_article |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Insomnia and Esketamine Add-On Therapy to Antidepressant Therapy in Patients with Treatment-Resistant Depression—A Pilot Study
by: Daniel Szawarnoga, et al.
Published: (2025-07-01) -
Case Report: Intranasal esketamine combined with a form of generative artificial intelligence in the management of treatment-resistant depression
by: Alexandre Fraichot, et al.
Published: (2025-08-01) -
Cost-per-remitter for esketamine nasal spray versus quetiapine for treatment-resistant depression
by: Kristin Clemens, et al.
Published: (2025-06-01) -
A randomized double-blind trial of intranasal dexmedetomidine versus intranasal esketamine for procedural sedation and analgesia in young children
by: Anna Nikula, et al.
Published: (2024-03-01) -
Case Report: Successful management of psychogenic non-epileptic seizures with intranasal esketamine
by: Muneeb Hashmi, et al.
Published: (2025-04-01)